Yaojen Chang1, Lorenzo Gallon, Kirti Shetty, Yuchia Chang, Colleen Jay, Josh Levitsky, Bing Ho, Talia Baker, Daniela Ladner, John Friedewald, Michael Abecassis, Gordon Hazen, Anton I Skaro. 1. 1 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. 2 Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, IL. 3 Division of Gastroenterology and Hepatology, Johns Hopkins University, Sibley Memorial Hospital, Washington, DC. 4 Division of Management, Policy and Community Health, University of Texas, School of Public Health, Houston, TX. 5 Department of Industrial Engineering and Management Sciences, McCormick School of Engineering, Northwestern University, Evanston, IL.
Abstract
BACKGROUND: Increasing use of kidney grafts for simultaneous liver and kidney (SLK) transplants is causing concern about the most effective utilization of scarce kidney graft resources. This study evaluated the impact of implementing the proposed United Network for Organ Sharing SLK transplant policy on outcomes for end-stage liver disease (ESLD) and end-stage renal disease (ESRD) patients awaiting transplant. METHODS: A Markov model was constructed to simulate a hypothetical cohort of ESLD patients over a 30-year time horizon starting from age 50. The model applies the different criteria being considered in the United Network for Organ Sharing policy and tallies outcomes, including numbers of procedures and life years after liver transplant alone (LTA) or SLK transplant. RESULTS: When 1-week pretransplant dialysis duration is required, the numbers of SLK transplants and LTAs would be 648 and 9,065, respectively. If the pretransplant dialysis duration is extended to 12 weeks, there would be 240 SLK transplants and 9,426 LTAs. This change results in a decrease of 6,483 life years among SLK transplant recipients and an increase of 4,971 life years among LTA recipients. However, by increasing the dialysis duration to 12 weeks from 1 week, 408 kidney grafts would be released to the kidney waitlist because of the decline in SLK transplants; this yields 796 additional life years gained among ESRD patients. CONCLUSION: Implementation of the proposed SLK transplant policy could restore access to kidney transplants for patients with ESRD albeit at the detriment of patients with ESLD and renal impairment.
BACKGROUND: Increasing use of kidney grafts for simultaneous liver and kidney (SLK) transplants is causing concern about the most effective utilization of scarce kidney graft resources. This study evaluated the impact of implementing the proposed United Network for Organ Sharing SLK transplant policy on outcomes for end-stage liver disease (ESLD) and end-stage renal disease (ESRD) patients awaiting transplant. METHODS: A Markov model was constructed to simulate a hypothetical cohort of ESLD patients over a 30-year time horizon starting from age 50. The model applies the different criteria being considered in the United Network for Organ Sharing policy and tallies outcomes, including numbers of procedures and life years after liver transplant alone (LTA) or SLK transplant. RESULTS: When 1-week pretransplant dialysis duration is required, the numbers of SLK transplants and LTAs would be 648 and 9,065, respectively. If the pretransplant dialysis duration is extended to 12 weeks, there would be 240 SLK transplants and 9,426 LTAs. This change results in a decrease of 6,483 life years among SLK transplant recipients and an increase of 4,971 life years among LTA recipients. However, by increasing the dialysis duration to 12 weeks from 1 week, 408 kidney grafts would be released to the kidney waitlist because of the decline in SLK transplants; this yields 796 additional life years gained among ESRDpatients. CONCLUSION: Implementation of the proposed SLK transplant policy could restore access to kidney transplants for patients with ESRD albeit at the detriment of patients with ESLD and renal impairment.
Authors: Uwe Siebert; Oguzhan Alagoz; Ahmed M Bayoumi; Beate Jahn; Douglas K Owens; David J Cohen; Karen M Kuntz Journal: Value Health Date: 2012 Sep-Oct Impact factor: 5.725
Authors: R A Wolfe; V B Ashby; E L Milford; A O Ojo; R E Ettenger; L Y Agodoa; P J Held; F K Port Journal: N Engl J Med Date: 1999-12-02 Impact factor: 91.245
Authors: Manish G Amin; Michael P Wolf; John A TenBrook; Richard B Freeman; Steve J Cheng; Daniel S Pratt; John B Wong Journal: Liver Transpl Date: 2004-12 Impact factor: 5.799
Authors: S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus Journal: Hepatology Date: 2001-05 Impact factor: 17.425
Authors: Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079
Authors: Mohsen Yaghoubi; Sonya Cressman; Louisa Edwards; Steven Shechter; Mary M Doyle-Waters; Paul Keown; Ruth Sapir-Pichhadze; Stirling Bryan Journal: Appl Health Econ Health Policy Date: 2022-08-09 Impact factor: 3.686
Authors: Mariya L Samoylova; Kara Wegermann; Brian I Shaw; Samuel J Kesseli; Sandra Au; Christine Park; Samantha E Halpern; Scott Sanoff; Andrew S Barbas; Yuval A Patel; Debra L Sudan; Carl Berg; Lisa M McElroy Journal: Liver Transpl Date: 2021-07-14 Impact factor: 6.112
Authors: Rohan M Modi; Dmitry Tumin; Andrew J Kruger; Eliza W Beal; Don Hayes; James Hanje; Anthony J Michaels; Kenneth Washburn; Lanla F Conteh; Sylvester M Black; Khalid Mumtaz Journal: World J Hepatol Date: 2018-01-27